替纳帕诺治疗便秘型肠易激综合征临床试验中腹部症状改善:一项事后分析
该事后分析汇总3项随机对照试验数据,评估替纳帕诺对便秘型肠易激综合征患者腹痛、不适、腹胀、痉挛和饱胀感的影响。共纳入1372例患者(替纳帕诺50mg每日两次684例,安慰剂688例),替纳帕诺组腹部评分较基线变化优于安慰剂组,且每周完全自发排便状态与腹部评分应答显著相关。
要点
- 替纳帕诺50mg每日两次较安慰剂显著改善腹部评分,最小二乘均值变化为-2.66 vs -2.09(P<0.0001)。
- 6/12周腹部评分应答率替纳帕诺组44.4% vs 安慰剂组32.4%(P<0.0001)。
- 每周完全自发排便状态与腹部评分应答显著相关(P<0.0001)。
核心结论
- 在便秘型肠易激综合征患者中,替纳帕诺较安慰剂显著减轻腹部症状,尤其是腹部评分所测的疼痛、不适和腹胀。
研究设计与样本
- 事后分析,汇总3项随机对照试验(NCT01923428、T3MPO-1 NCT02621892、T3MPO-2 NCT02686138)的腹部症状数据,共1372例患者(替纳帕诺50mg每日两次684例,安慰剂688例)。
主要发现
- 腹部评分较基线的最小二乘均值变化:替纳帕诺组-2.66 vs 安慰剂组-2.09(P<0.0001)。
- 6/12周腹部评分应答率:替纳帕诺组44.4% vs 安慰剂组32.4%(P<0.0001)。
- 9/12周腹部评分应答率:替纳帕诺组30.6% vs 安慰剂组20.5%(P<0.0001)。
- 每周完全自发排便状态与每周腹部评分应答状态显著相关(P<0.0001),每周完全自发排便>0的患者中达到腹部评分降低的比例更高。
关键数值与推荐
- 腹部评分定义为腹痛、不适和腹胀每周评分的平均值。
- 腹部评分应答定义为改善≥2分持续≥6/12周或≥9/12周。
- 每周腹部评分应答状态定义为降低≥30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This post hoc analysis evaluated the efficacy of tenapanor on abdominal symptoms in patients with irritable bowel syndrome with constipation. Abdominal symptoms assessed included pain, discomfort, bloating, cramping, and fullness. METHODS: The abdominal symptom data were pooled from 3 randomized controlled trials (NCT01923428, T3MPO-1 [NCT02621892], and T3MPO-2 [NCT02686138]). Weekly scores were calculated for each abdominal symptom, and the Abdominal Score (AS) was derived as the average of weekly scores for abdominal pain, discomfort, and bloating. The overall change from baseline during the 12 weeks was assessed for each symptom weekly score and the AS. The AS 6/12-week and 9/12-week response rates (AS improvement of ≥2 points for ≥6/12- or ≥9/12-week) were also evaluated. The association of weekly AS response status (reduction of ≥30%) with weekly complete spontaneous bowel movement (CSBM) status (=0 and >0) was assessed. RESULTS: Among 1,372 patients (684 tenapanor [50 mg twice a day] and 688 placebo), the least squares mean change from baseline in AS was -2.66 for tenapanor vs -2.09 for placebo ( P < 0.0001). The 6/12-week AS response rate was 44.4% for tenapanor vs 32.4% for placebo ( P < 0.0001), and for 9/12-week AS, 30.6% for tenapanor vs 20.5% for placebo ( P < 0.0001). A significant association between weekly CSBM status and weekly AS response status was observed each week ( P < 0.0001), with a greater proportion achieving an AS reduction in patients with >0 CSBMs in a week. DISCUSSION: Tenapanor significantly reduced abdominal symptoms in patients with irritable bowel syndrome with constipation, particularly pain, discomfort, and bloating measured by AS, compared with placebo.
引用
- Lembo AJ, Chey WD, Harris LA, et al. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis. Am J Gastroenterol. 2024. PMID: 38294158. doi:10.14309/ajg.0000000000002685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。